Show simple item record

dc.contributor.authorBrown, Marc
dc.date.accessioned2014-06-11T15:00:36Z
dc.date.available2014-06-11T15:00:36Z
dc.date.issued2005-11-01
dc.identifier.citationBrown , M 2005 , ' The lost science of formulation ' , Drug Discovery Today , vol. 10 , no. 21 , pp. 1405-1407 . https://doi.org/10.1016/S1359-6446(05)03643-3
dc.identifier.issn1359-6446
dc.identifier.otherPURE: 628160
dc.identifier.otherPURE UUID: 8bd1c22a-70a1-4200-9f41-9303900055d7
dc.identifier.otherWOS: 000232575400001
dc.identifier.otherScopus: 26944440888
dc.identifier.urihttp://hdl.handle.net/2299/13710
dc.description.abstractThe current R&D outsourcing market is growing annually at ∼15%, with a predicted market of US$36 billion by 2010. However, top tier contract research organizations (CROs) are attempting to transform their profitability by focusing on higher value-added services, such as preclinical and bioanalytical testing, leading to a shortage of high-quality formulation CROsen
dc.format.extent3
dc.language.isoeng
dc.relation.ispartofDrug Discovery Today
dc.titleThe lost science of formulationen
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionPharmaceutics
dc.contributor.institutionSkin and Nail Group
dc.contributor.institutionAirway Group
dc.contributor.institutionBioadhesive Drug Delivery Group
dc.contributor.institutionNanopharmaceutics
dc.contributor.institutionPharmaceutical Analysis and Product Characterisation
dc.description.statusPeer reviewed
rioxxterms.versionofrecordhttps://doi.org/10.1016/S1359-6446(05)03643-3
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record